Prilenia Raises $43M to Advance Plans for Pridopidine

Prilenia Raises $43M to Advance Plans for Pridopidine

312449

Prilenia Raises $43M to Advance Plans for Pridopidine

Prilenia Therapeutics has raised $43 million to support potential regulatory submissions and marketing of its lead candidate, pridopidine, for the treatment of amyotrophic lateral sclerosis (ALS). The funding, obtained through a Series B financing round, also will be used to support the potential marketing of the candidate therapy for Huntington’s disease, to speed timelines, plan for additional indications, and to expand the company’s executive team and operations. “With the support of this group of leading investors, we…

You must be logged in to read/download the full post.